Načítá se...
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Today, monoclonal antibodies (mAbs) are a widespread and necessary tool for biomedical science. In the hematological cancer field, since rituximab became the first mAb approved by the Food and Drug Administration for the treatment of B-cell malignancies, a number of effective mAbs targeting lineage-...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2018-01-01
|
| Edice: | Frontiers in Immunology |
| Témata: | |
| On-line přístup: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01936/full |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|